|Status : Upcoming||Report Code : VRHC1034||Industry : Healthcare||Available Format :|
Cell signaling is complicated interactive system that controls and intermediates numerous cellular reactions in the human body. These signaling pathways chiefly comprise of proteins that can interact, progress to particular locations. The global cell signaling market is growing at significant rate, due to mounting occurrence of chronic diseases and technological improvements in cell-based research instruments. Different products contributed to the cell signaling market size. The market has witnessed high demand for consumables over the last few years due to mounting occurrence of chronic diseases.
Insight by Product
There are two products of cell signaling, consumables and instruments. Of both, consumables market witnessed the higher growth worldwide, which is due to mounting occurrence of chronic diseases and escalating number of research activities. The consumables are further sub divided into reagents, antibodies, assay kits and others. Antibodies accounted the largest share in the consumables cell signaling market due to its extensive applicability in molecular biology, and its essential function in mapping, disease detection, and structural analysis.
Insight by Signaling Type
On the basis of signaling type the market is subdivided into juxtacrine signaling, endocrine signaling, autocrine signaling, paracrine signaling and others. Of all, endocrine signaling market witnessed the highest growth in the market.
Insight by Technology
On the basis of technology the market is subdivided into Elisa, microscopy, western blotting, mass spectrometry, immunohistochemistry, flow cytometry and other. Of all, microscopy segment witnessed the highest growth in the market.
Insight by Pathway
There are various types of pathways, JAK/STAT signaling pathway, AKT signaling pathway, hedgehog signaling pathway, AMPK signaling pathway, notch signaling pathway, ErbB /HER signaling pathway, NF-KB signaling pathway and others. Extensively accepted in elementary research and drug development and AKT associated in diseases such as diabetes, cancer, and neuro-degeneration are some of the factors responsible for the growth of the AKT signaling pathway segment. Of all the pathways, the AKT signaling pathway anticipated to account the foremost share in the cell signaling market.
Insight by Application
There are two applications, medical and research. Among the all applications, the research application is expected to command the cell signaling market due to mounting applicability in cancer research.
The mounting occurrence of chronic diseases, accessibility of finance for cell-based research, technological improvements in cell-based research instruments and progress of biopharmaceuticals and life science industries are the primary growth drivers for cell signaling industry. For instance, according to Centers for Disease Control and Prevention in 2012, approximately 117 million people in the U.S. had one or the more chronic conditions.
Development of microfluidics in cell biology research, expanding geriatric population, mounting applicability of cell signaling in biotechnology and improved life science infrastructure are also facilitating the growth for the cell signaling market.
The high cost of system, and complexities related to reagent and antibody development are the major challenges for the growth of cell signaling market. The socio-ethical issues involved in stem cell research such as religious briefs and destruction of human embryo are considered as the hindering factor for the market.
Globally, the manufacturing companies trying to enter the cell signaling market are required to maintain stringent regulatory standards. Moreover, the high level of capital requirement also poses a major barrier for the entry of new players. This offers an edge to the established players in the industry competition.
Geographically, North America is the largest cell signaling market as in the region the occurrence of chronic disease is increasing. For instance, according to GLOBOCAN in the U.S. approximately 1.6 million new cancer cases were diagnosed and there were 0.6 million cancer deaths in 2012. In addition, the healthcare expenditure is increasing in North America, which has increased the accessibility and affordability of treatment among the individuals. Expanding geriatric population, large number of research institutes and improved life science infrastructure are also up surging growth of the North American cell signaling market.
Asia-Pacific is observed to witness fastest growth in the market, as the region comprises of large population base. In addition, mounting occurrence of chronic diseases, boosting research and development activities, budding partnership of main players with local manufacturer, expanding geriatric population and improving life science infrastructure are also creating a positive impact on the cell signaling market growth in the region.
Key players in the cell signaling market are catering the demand of these devices by investing on technologically advanced products in their product portfolio across the globe. Cell Signaling Technology has commenced an office in Shanghai China, to encourage the swiftly multiplying China life science market. In addition, June 2018, Bio-Techne Corporation acquired Exosome Diagnostics, Inc., to integrate its product portfolio. Merck KGaA, Cell Signaling Technology, Inc., Perkinelmer, Inc., Thermo Fisher Scientific Inc., Qiagen N.V., Becton, Dickinson and Company, Beckman Coulter Inc., Promega Corporation, Bio-Rad Laboratories, Inc., and Bio-Techne Corporation are the key players offering products.